PDF(Pubmed)
Abstract：
BACKGROUND: In cases of coronavirus disease 2019 (COVID-19), favipiravir is commonly included to the therapy regimen. Drug interactions between favipiravir and other COVID-19 therapy drugs are frequently researched. However, no research on possible drug interactions between Favipiravir and radiocontrast agents, which have become almost crucial in diagnostic processes while not being part of the treatment, has been found.
OBJECTIVE: To determine potential medication interactions between Favipiravir and radiocontrast agents.
METHODS: The study comprised patients who were taking Favipiravir for COVID-19 therapy and underwent a contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) test while taking the medicine. The computerized patient files of the cases included in the study, as well as the pharmacovigilance forms in the designated hospital, were evaluated for this purpose.
RESULTS: The study included the evaluation of data from 1046 patients. The study sample\'s mean age was 47.23 ± 9.48 years. The mean age of cases with drug interactions was statistically significant greater than that of cases with no drug interactions (P = 0.003). When evaluated with logistic regression analysis, a 1-year raises in age increases the risk of developing drug interactions by 1.63 times (P = 0.023). There was no statistically significant difference in the occurrence of medication interactions between the sexes (P = 0.090). Possible medication interactions were discovered in 42 cases (4%).
CONCLUSIONS: The findings of this study revealed that the most notable findings as a result of the combined use of contrast agents and favipiravir were increased creatinine and transaminase values, as well as an increase in the frequency of nausea and vomiting. The majority of drug interactions discovered were modest enough that they were not reflected in the clinic. Drug interactions become more common as people get older.
OBJECTIVE: To determine potential medication interactions between Favipiravir and radiocontrast agents.
METHODS: The study comprised patients who were taking Favipiravir for COVID-19 therapy and underwent a contrast-enhanced computed tomography (CT) or magnetic resonance imaging (MRI) test while taking the medicine. The computerized patient files of the cases included in the study, as well as the pharmacovigilance forms in the designated hospital, were evaluated for this purpose.
RESULTS: The study included the evaluation of data from 1046 patients. The study sample\'s mean age was 47.23 ± 9.48 years. The mean age of cases with drug interactions was statistically significant greater than that of cases with no drug interactions (P = 0.003). When evaluated with logistic regression analysis, a 1-year raises in age increases the risk of developing drug interactions by 1.63 times (P = 0.023). There was no statistically significant difference in the occurrence of medication interactions between the sexes (P = 0.090). Possible medication interactions were discovered in 42 cases (4%).
CONCLUSIONS: The findings of this study revealed that the most notable findings as a result of the combined use of contrast agents and favipiravir were increased creatinine and transaminase values, as well as an increase in the frequency of nausea and vomiting. The majority of drug interactions discovered were modest enough that they were not reflected in the clinic. Drug interactions become more common as people get older.
摘要：
背景：在2019年冠状病毒病（COVID-19）的病例中，favipirravir通常包括在治疗方案中。favipirravir和其他COVID-19治疗药物之间的药物相互作用经常被研究。然而,没有关于Favipiravir和放射性造影剂之间可能的药物相互作用的研究，在诊断过程中几乎变得至关重要，而不是治疗的一部分，已被发现。
目的：确定Favipiravirvir与放射性造影剂之间潜在的药物相互作用。
方法：该研究包括正在服用Favipiravir进行COVID-19治疗并在服药期间接受对比增强计算机断层扫描（CT）或磁共振成像（MRI）测试的患者。纳入研究的病例的计算机化患者档案，以及指定医院的药物警戒表格，为此目的进行了评估。
结果：该研究包括对1046例患者数据的评估。研究样本的平均年龄为47.23±9.48岁。有药物相互作用的病例的平均年龄在统计学上显著大于无药物相互作用的病例(P=0.003)。当用逻辑回归分析评估时，年龄增加1年,发生药物相互作用的风险增加1.63倍(P=0.023).性别差异无统计学意义(P=0.090)。42例（4％）发现了可能的药物相互作用。
结论：这项研究的结果表明，联合使用造影剂和favipiraviravir最显著的发现是肌酐和转氨酶值升高，以及恶心和呕吐的频率增加。所发现的大多数药物相互作用都是适度的，以至于在临床上没有反映出来。随着年龄的增长，药物相互作用变得越来越普遍。
目的：确定Favipiravirvir与放射性造影剂之间潜在的药物相互作用。
方法：该研究包括正在服用Favipiravir进行COVID-19治疗并在服药期间接受对比增强计算机断层扫描（CT）或磁共振成像（MRI）测试的患者。纳入研究的病例的计算机化患者档案，以及指定医院的药物警戒表格，为此目的进行了评估。
结果：该研究包括对1046例患者数据的评估。研究样本的平均年龄为47.23±9.48岁。有药物相互作用的病例的平均年龄在统计学上显著大于无药物相互作用的病例(P=0.003)。当用逻辑回归分析评估时，年龄增加1年,发生药物相互作用的风险增加1.63倍(P=0.023).性别差异无统计学意义(P=0.090)。42例（4％）发现了可能的药物相互作用。
结论：这项研究的结果表明，联合使用造影剂和favipiraviravir最显著的发现是肌酐和转氨酶值升高，以及恶心和呕吐的频率增加。所发现的大多数药物相互作用都是适度的，以至于在临床上没有反映出来。随着年龄的增长，药物相互作用变得越来越普遍。
